Quarterly report · Q2
4361.TEDINET S100RBST
Period2022-12-01 → 2023-05-31
Filed2023-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2022-12-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.9bn | 2021-12-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | ¥156m | 2022-12-01 → 2023-05-31 | Cons. | Operating income |
| Operating income | ¥226m | 2021-12-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | ¥156m | 2022-12-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥235m | 2021-12-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥155m | 2022-12-01 → 2023-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥234m | 2021-12-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥121m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥179m | 2021-12-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥121m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss |
| Net income | ¥179m | 2021-12-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥7.8bn | at 2022-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.5bn | at 2023-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.9bn | at 2022-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.5bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥999m | at 2023-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥911m | at 2022-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥999m | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥984m | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2021-11-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥223m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21m | 2021-12-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥124m | 2021-12-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥217m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥243m | 2021-12-01 → 2022-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥121m | 2021-12-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥80m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥162m | 2021-12-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥104m | 2021-12-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.17 | 2022-12-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.39 | 2023-03-01 → 2023-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.06 | 2021-12-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.82 | 2022-03-01 → 2022-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 31.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.6% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥141m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-05-31 | ¥156m |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2021-12-01 → 2022-05-31 | ¥3.9bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2021-12-01 → 2022-05-31 | ¥3.9bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2021-12-01 → 2022-05-31 | ¥211m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2021-12-01 → 2022-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2021-12-01 → 2022-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2021-12-01 → 2022-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-12-01 → 2022-05-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-12-01 → 2022-05-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-12-01 → 2022-05-31 | ¥226m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 469
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -335645000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 88421000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1319778000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 910919000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 984133000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 999341000 | JPY |
| Employee payrolls and allowances sga | Prior1YTDDuration | 136979000 | JPY |
| Employee payrolls and allowances sga | CurrentYTDDuration | 143080000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 29042000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 21333000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 6000000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 5400000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 8350000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 5400000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 115824000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 112952000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 3927014000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 18995000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3946010000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 3946010000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 3927014000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 18995000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3946010000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 3946010000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 211104000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 15191000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 226296000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 226296000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4187724000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19179000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4206904000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 4206904000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4187724000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19179000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4206904000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |